Citius Oncology, Inc. CTOR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s additional paid-in capital?
- Citius Oncology, Inc. (CTOR) reported additional paid-in capital of $131.44M in Q1 2026.
- How has Citius Oncology, Inc.'s additional paid-in capital changed year-over-year?
- Citius Oncology, Inc.'s additional paid-in capital increased by 47.2% year-over-year, from $89.31M to $131.44M.
- What is the long-term trend for Citius Oncology, Inc.'s additional paid-in capital?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s additional paid-in capital has grown at a 1536.9% compound annual growth rate (CAGR), from $24.83K to $108.9M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.